Bill Text: NH SB477 | 2018 | Regular Session | Enrolled

---

Bill Title: Establishing a therapeutic cannabis medical oversight board.

Spectrum: Bipartisan Bill

Status: (Passed) 2018-06-14 - Signed by the Governor on 06/08/2018; Chapter 0228; Effective 08/07/2018 [SB477 Detail]

Download: New_Hampshire-2018-SB477-Enrolled.html

---

SB 477 - VERSION ADOPTED BY BOTH BODIES

 

02/01/2018   0306s

05/10/2018   1935EBA

 

2018 SESSION

18-3017

01/10

 

SENATE BILL 477

 

AN ACT establishing a therapeutic cannabis medical oversight board.

 

SPONSORS: Sen. Fuller Clark, Dist 21; Sen. Bradley, Dist 3; Sen. Watters, Dist 4; Sen. Reagan, Dist 17; Rep. Kotowski, Merr. 24; Rep. Knirk, Carr. 3

 

COMMITTEE: Health and Human Services

 

─────────────────────────────────────────────────────────────────

 

AMENDED ANALYSIS

 

This bill establishes the therapeutic cannabis medical oversight board which shall monitor and contribute to the oversight of the clinical, quality, and public health related matters of the use of cannabis for therapeutic purposes law under RSA 126-X.

 

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

 

Explanation: Matter added to current law appears in bold italics.

Matter removed from current law appears [in brackets and struckthrough.]

Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.

02/01/2018   0306s

05/10/2018   1935EBA 18-3017

01/10

 

STATE OF NEW HAMPSHIRE

 

In the Year of Our Lord Two Thousand Eighteen

 

AN ACT establishing a therapeutic cannabis medical oversight board.

 

Be it Enacted by the Senate and House of Representatives in General Court convened:

 

1  New Paragraph; Use of Cannabis for Therapeutic Purposes; Rules.  Amend RSA 126-X:6 by inserting after paragraph III the following new paragraph:

IV.  The department shall adopt rules relative to the therapeutic cannabis medical oversight board's public hearing process pursuant to RSA 126-X:12, V.

2  New Section; Use of Cannabis for Therapeutic Purposes; Therapeutic Cannabis Medical Oversight Board.  Amend RSA 126-X by inserting after section 11 the following new section:

126-X:12  Therapeutic Cannabis Medical Oversight Board Established; Membership; Duties.

I.  There is hereby established the therapeutic cannabis medical oversight board which shall monitor and contribute to the oversight of the clinical, quality, and public health related matters of the use of cannabis for therapeutic purposes under this chapter.

II.  The board shall consist of the medical director, department of health and human services, or designee, a qualifying patient, appointed by the commissioner of the department, a clinical representative from an alternative treatment center, appointed by the commissioner, and 10 medical providers also appointed by the commissioner.  The medical provider members shall represent the following fields:

(a)  Neurology.

(b)  Pain management.

(c)  Oncology.

(d)  Psychiatry.

(e)  Pediatrics.

(f)  Family or internal medicine.

(g)  Obstetrics and gynecology.

(h)  Addiction.

(i)  Palliative care.

(j)  Physiatry/orthopedics.

III.  At its first meeting the board shall elect by majority vote a chairperson and an alternate.  A quorum shall consist of a majority of members.

IV.  The board shall convene at least 2 times per year to monitor and contribute to the oversight of the clinical, quality, and public health related matters of therapeutic cannabis under this chapter by:

(a)  Reviewing medical and scientific evidence pertaining to currently approved and additional qualifying conditions.

(b)  Reviewing laboratory results of required testing of cannabis cultivated and/or processed by an alternative treatment center and the use of pesticides on products under  RSA 126-X:6, III(a)(16).

(c)  Monitoring clinical outcomes.

(d)  Reviewing training protocols for dispensary staff based on models from other states.

(e)  Receiving updates from alternative treatment centers on effectiveness of various strains, types of cannabinoids, and different routes of administration for specific conditions.

(f)  Reviewing best practices for medical providers regarding provider education, certification of patients, and patient access to the program.

(g)  Reviewing any other clinical, quality, and public health related matter relative to use of cannabis under this chapter.

V.  The board may make recommendations to the commissioner to add or remove qualifying medical conditions under RSA 126-X:1, IX based on the findings pursuant to subparagraph IV(a) and after receiving input from the public through a public hearing process.  The commissioner may recommend legislation based on the board’s findings.

VI.  On or before January 1 of each year, the board shall make a report to the president of the senate, the speaker of the house of representatives, the oversight committee on health and human services established under RSA 126-A:13, the board of medicine, the board of nursing, and the therapeutic use of cannabis advisory council established in RSA 126-X:9.

3  Contingent Renumbering.  If SB 388 of the 2018 regular legislative session becomes law, RSA 126-X:6, IV, as inserted by section 1 of this act, shall be renumbered as RSA 126-X:6, V.

4  Effective Date.  This act shall take effect 60 days after its passage.